ASCELIA PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.16 SEK | +5.28% |
|
-15.33% | +231.16% |
Presenter SpeechMagnus Corfitzen (Executives)Thank you, and welcome, everyone, to the webcast ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Calendar
2024-05-05
- Annual General Meeting
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +231.16% | 34.36M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ACE Stock
- News Ascelia Pharma AB
- Transcript : Ascelia Pharma AB, H1 2023 Earnings Call, Aug 18, 2023
